Literature DB >> 32696992

Specific macrophage subsets accumulate in human subcutaneous and omental fat depots during obesity.

Angélica Girón-Ulloa1, Erika González-Domínguez1, Rebeca S Klimek1, Eduardo Patiño-Martínez1, Germán Vargas-Ayala2, Norma C Segovia-Gamboa1, Victoria Campos-Peña3, Martha E Rodríguez-Arellano4, Marco A Meraz-Ríos1, Salvador F Campos-Campos5, Carmen Sánchez-Torres1.   

Abstract

Obesity is a chronic inflammatory disease associated with adipose tissue macrophage (ATM) activation. ATMs from lean mice contribute to tissue homeostasis by their M2-oriented polarization, whereas obesity leads to an increase of M1 inflammatory ATMs that underlies obesity-related metabolic disorders. In humans, studies characterizing ATMs and their functional status are limited. Here we investigated ATM phenotype in visceral (VAT) and subcutaneous (SAT) adipose tissue from healthy lean and obese individuals using two molecules previously identified as markers of M1-like and M2-like/tissue-resident macrophages, the C-type lectin CLEC5A and the scavenger receptor CD163L1, respectively. CD163L1 was expressed by the majority of ATMs, and CD163L1+ ATM density was greater with respect to cells expressing the pan-macrophage markers CD68 or CD11b. ATM counts in SAT, but not in VAT, increased in obese compared to lean individuals, measured with the three markers. Accordingly, CD163L1, CD68 and ITGAM gene expression was significantly enhanced in obese with respect to control individuals only in SAT. CLEC5A+ ATMs had a proinflammatory profile and were abundant in the lean VAT, but their density diminished in obesity. The only ATM subset that increased its counts in the obese VAT had a mixed M1-like (CD11c+ CD163- CD209- ) and M2-like (CLEC5A- CD206+ ) phenotype. ATM expansion was dominated by a subset of M2-like macrophages (CD11c- CLEC5A- CD163+ CD206+ CD209+ ) in the obese SAT, with a minor contribution of a CD11c+ CLEC5A- ATM subpopulation. Thus, both SAT and VAT seems to limit inflammation during obesity by differentially altering their ATM subset composition.
© 2020 Australian and New Zealand Society for Immunology Inc.

Entities:  

Keywords:  CD163L1; CLEC5A; human adipose tissue; macrophage; obesity; subcutaneous; visceral

Year:  2020        PMID: 32696992     DOI: 10.1111/imcb.12380

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  6 in total

Review 1.  Adipose Tissue Inflammation and Cardiovascular Disease: An Update.

Authors:  Mariam N Rana; Ian J Neeland
Journal:  Curr Diab Rep       Date:  2022-02-18       Impact factor: 4.810

2.  Screening of Bovine Tissue-Specific Expressed Genes and Identification of Genetic Variation Within an Adipose Tissue-Specific lncRNA Gene.

Authors:  Sihuan Zhang; Han Xu; Enhui Jiang; Zhanerke Akhatayeva; Fugui Jiang; Enliang Song; Chuanying Pan; Hong Chen; Xianyong Lan
Journal:  Front Vet Sci       Date:  2022-05-11

3.  The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient".

Authors:  Melissa Bersanelli; Alessio Cortellini; Sebastiano Buti
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

Review 4.  Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases.

Authors:  Ibrahim AlZaim; Safaa H Hammoud; Houssam Al-Koussa; Alaa Ghazi; Ali H Eid; Ahmed F El-Yazbi
Journal:  Front Cardiovasc Med       Date:  2020-11-17

5.  TRPV4 Plays a Role in Matrix Stiffness-Induced Macrophage Polarization.

Authors:  Bidisha Dutta; Rishov Goswami; Shaik O Rahaman
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 6.  Adipose Tissue Development and Expansion from the Womb to Adolescence: An Overview.

Authors:  Camila E Orsso; Eloisa Colin-Ramirez; Catherine J Field; Karen L Madsen; Carla M Prado; Andrea M Haqq
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.